Key Dates

Related Announcements

RFA-DA-21-019 - Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This Notice informs interested applicants that funding opportunity announcement RFA-DA-21-019 “Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)” has been amended to add an additional submission date.

The FOA has been modified as follows:

Currently Reads:

Part 1. Overview Information, Key Dates

Open Date (Earliest Submission Date): June 20, 2020

Letter of Intent Due Date(s): June 20, 2020

Application Due Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s): July 20, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Scientific Merit Review: November 2020

Advisory Council Review: January 2021

Earliest Start Date: April 2021

Expiration date: July 21, 2020

Part 2, Full Text of Announcement, Section 1 Funding Opportunity Description

Goals: The purpose of this FOA is to support generation of single cell RNA-sequencing datasets for at least one brain region relevant to persistent HIV infection and opioid, cocaine and/or methamphetamine use disorder. Applications that are not responsive to this FOA will not be reviewed. In order to be responsive to this FOA, proposed projects MUST be framed to answer one or more vexing questions about persistent HIV infection in the CNS. The major thrust of the proposed project also MUST:

• • exploit single nucleus or single cell transcriptomic assays with the goal of identifying cell types and/or cell states in at least one NIDA-relevant brain region (e.g. PFC, NAc, VTA, striatum, insula, or other appropriately justified region), and
  • focus on rodent, primate, or human post-mortem brain tissue, and
  • propose to analyze samples from rodents, primates, and/or humans that include 1. controls, 2. chronic opioid, cocaine and/or methamphetamine exposure, 3. HIV-infected individuals or animal models of HIV/SIV infection, and 4. HIV-infected individuals or animal models of HIV/SIV infection with chronic opioid, cocaine, and/or methamphetamine exposure.

Part 2, Full Text of Announcement, Section II Award information

Application types allowed New

Funds Available and Anticipated Number of Awards NIDA intends to commit $5M in FY21 to fund 1-4 applications

Section V. Application Review Information, Additional Review Criteria

Resubmission Not applicable.

Revised to Read:

Part 1. Overview Information, Key Dates

Open Date (Earliest Submission Date): June 20, 2020

Letter of Intent Due Date(s): June 20, 2020, June 20, 2021

Application Due Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s): July 20, 2020 and July 20, 2021

All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Scientific Merit Review: November, 2020, November, 2021

Advisory Council Review: January 2021, January 2022

Earliest Start Date: April 2021

Expiration Date: July 21, 2021

Part 2, Full Text of Announcement, Section 1 Funding Opportunity Description

Goals: The purpose of this FOA is to support generation of single cell RNA-sequencing datasets for at least one brain region relevant to persistent HIV infection and opioid, cocaine, methamphetamine and/or cannabis use disorder. Applications that are not responsive to this FOA will not be reviewed. In order to be responsive to this FOA, proposed projects MUST be framed to answer one or more vexing questions about persistent HIV infection in the CNS. The major thrust of the proposed project also MUST:

• • exploit single nucleus or single cell transcriptomic assays with the goal of identifying cell types and/or cell states in at least one NIDA-relevant brain region (e.g. PFC, NAc, VTA, striatum, insula, or other appropriately justified region), and
  • focus on rodent, primate, or human post-mortem brain tissue, and
  • propose to analyze samples from rodents, primates, and/or humans that include 1. controls, 2. chronic opioid, cocaine, methamphetamine and/or cannabinoid exposure, 3. HIV-infected individuals or animal models of HIV/SIV infection, and 4. HIV-infected individuals or animal models of HIV/SIV infection with chronic opioid, cocaine, methamphetamine, and/or cannabinoid exposure.

Part 2, Full Text of Announcement, Section II Award information

Application types allowed New, Resubmission

Funds Available and Anticipated Number of Awards NIDA intends to commit $5M in FY21 to fund 1-4 applications and $4M in FY22 to fund 1-4 applications

Section V. Application Review Information, Additional Review Criteria

Resubmissions: For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

John Satterlee, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1020
Email:satterleej@nida.nih.gov